NCT00002970View on ClinicalTrials.gov

506U78 in Treating Patients With Refractory Hematologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

January 31, 2005

Conditions
Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic LymphomaT-cell Childhood Acute Lymphoblastic Leukemia
Interventions
DRUG

nelarabine

Given IV

DRUG

methotrexate

Given IT

DRUG

cytarabine

Given IT

DRUG

therapeutic hydrocortisone

Given IT

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
collaborator

Children's Cancer Group

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT00002970 - 506U78 in Treating Patients With Refractory Hematologic Cancer | Biotech Hunter | Biotech Hunter